Viewing Study NCT05164458


Ignite Creation Date: 2025-12-25 @ 12:08 AM
Ignite Modification Date: 2025-12-25 @ 12:08 AM
Study NCT ID: NCT05164458
Status: RECRUITING
Last Update Posted: 2023-12-28
First Post: 2021-11-25
Is Possible Gene Therapy: False
Has Adverse Events: False

Brief Title: Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module